ESM1 and Familial prostate cancer: Endocan may be a key player in sustaining tumor growth and recent microarray analyses identified endocan, among other genes, as being one of the most significant molecular signatures defining a poor prognosis in breast [18], lung [19] but also in prostate cancers [20].